{"id":"W2480832378","doi":"10.17925/ee.2014.10.02.98","title":"The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?","year":2014,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Receptor; Diabetes mellitus; Agonist; Endocrinology; Pharmacology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002830011,0.001319033,0.001876369,0.001590621,0.0008066422,0.002697554,0.001476287,0.004656938,0.005971589],"category_scores_gemma":[0.005790079,0.0004103905,0.001044622,0.0008322825,0.001378326,0.004381203,0.001075997,0.009747213,0.004802564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052319,"about_ca_system_score_gemma":0.001045869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004498145,"about_ca_topic_score_gemma":0.001192645,"domain_scores_codex":[0.9985266,0.0004345375,0.0001911375,0.0001426751,0.0006335581,0.00007139182],"domain_scores_gemma":[0.9957645,0.002354274,0.0002649887,0.0001014086,0.001073652,0.0004411316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008151299,0.00004116366,0.0000356036,0.001733026,0.00005020423,0.000223751,0.000068336,0.00006576134,0.0002699428,0.002362951,0.879537,0.1155307],"study_design_scores_gemma":[0.00002187201,0.00003361493,0.00009596382,0.0006393788,0.00002587876,0.0004238308,0.00004015116,0.00003155182,0.00004540283,0.001364259,0.9972686,0.000009523967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"editorial","genre_scores_codex":[0.0001233835,0.5260892,0.0003053084,0.04635065,0.4236546,0.00001509058,0.00002275084,0.0000508041,0.003388288],"genre_scores_gemma":[0.000902394,0.3994431,0.0004834898,0.03205177,0.5578583,0.00002137799,0.00003617307,0.00003698529,0.009166332],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.005971589,"threshold_uncertainty_score":0.01997691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00987615569664187,"score_gpt":0.2814787907792313,"score_spread":0.2716026350825895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}